they already have a liquid formulation underway. If bioequvialence is the same then safety trial required. They do have a liquid formulation but it was unpalatable so hopefully just a couple of tweaks required.
they are proceeding with P2/3 H2 so proceeding for registration under ODD accelerated approval. By that stage Pharma could scoop up with liquid formulation developed.
I wonder whether FDA would have an issue with the oral tablet given ALS can cause difficulty swallowing. This is also an exclusion to the trial. However, this pathway has been ok’d by the FDA in the past.
Rilutek (oral formulation)
Tiglutik (reformulation to oral suspension)
Exservan (reformulation oral film)
This seems like a proven pathway as the current formulation can still be used unless difficulty swallowing occurs.
Not like an RC110 to RC220 scenario.
- Forums
- ASX - By Stock
- PAA
- Pipeline-in-a-drug
Pipeline-in-a-drug, page-28
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.55M |
Open | High | Low | Value | Volume |
18.0¢ | 18.0¢ | 17.5¢ | $36.85K | 205.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 162181 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 412357 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 162181 | 0.175 |
13 | 401984 | 0.170 |
7 | 256513 | 0.165 |
8 | 396304 | 0.160 |
7 | 336735 | 0.155 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 412357 | 6 |
0.185 | 267471 | 5 |
0.190 | 772743 | 8 |
0.195 | 540777 | 9 |
0.200 | 302726 | 11 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |